酚妥拉明联合垂体后叶素治疗肺结核顽固性咯血的疗效分析

发布时间：2019-06-03 04:31

【摘要】：目的:探讨酚妥拉明联合垂体后叶素治疗肺结核顽固性咯血的临床疗效。方法:选取我院2013年10月至2016年10月收治的84例肺结核顽固性咯血患者为研究对象,将所有患者根据入院顺序分为对照组和研究组,每组42例,对照组患者单用垂体后叶素静脉滴注,研究组在对照组的基础上联合酚妥拉明静脉滴注,对比两组患者的治疗效果及不良反应发生情况。结果:研究组咯血停止时间为(1.51±0.48)d,治疗总有效率为92.86%(39/42),不良反应发生率为7.14%(3/42),对照组咯血停止时间为(3.17±0.56)d,治疗总有效率为76.19%(32/42),不良反应发生率为28.57%(12/42),两组比较差异性显著(P0.05)。结论:酚妥拉明联合垂体后叶素能有效的提高肺结核顽固性咯血的临床疗效显著,且不良反应少,具有一定的临床应用价值。
[Abstract]:Objective: to investigate the clinical effect of phentolamine combined with Pituitrin in the treatment of refractory hemoptysis of pulmonary tuberculosis. Methods: from October 2013 to October 2016, 84 patients with refractory hemoptysis of pulmonary tuberculosis were selected and divided into control group (n = 42) and study group (n = 42) according to the order of admission. The patients in the control group were treated with Pituitrin alone, and the patients in the study group were treated with phentolamine intravenous drip on the basis of the control group. The therapeutic effects and adverse reactions of the two groups were compared. Results: the stopping time of hemoptysis was (1.51 卤0.48) days in the study group, the total effective rate was 92.86% (39 鈮，

本文编号：2491670